NCT04713709View on ClinicalTrials.gov

A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder

PHASE1CompletedINTERVENTIONAL
Enrollment

46

Participants

Timeline

Start Date

January 31, 2021

Primary Completion Date

March 30, 2021

Study Completion Date

October 10, 2021

Conditions
Opioid Overdose
Interventions
COMBINATION_PRODUCT

Nasus Pharma FMXIN001

A nasal spray of 4mg Naloxone Hydrochloride powder in a unit dose device

COMBINATION_PRODUCT

Nasal Naloxone liquid spray

A nasal spray of 4mg/0.1mL Naloxone Hydrochloride solution in a unit dose device

Trial Locations (1)

L5R 0B7

Pharma Medica Research Inc, Mississauga

Sponsors

Lead Sponsor

Nasus Pharma
All Listed Sponsors
lead

Nasus Pharma

INDUSTRY

NCT04713709 - A Single-Dose, Bioequivalence Study of FMXIN001 4 mg Microspheres Powder | Biotech Hunter | Biotech Hunter